AGM Statement

Alliance Pharma PLC
15 June 2004



For Immediate Release



                         ALLIANCE PHARMA PLC (AIM: APH)

                         ('Alliance' or 'the Company')

                      Annual General Meeting 15 June 2004



At Alliance Pharma's Annual General Meeting, held today in London, all
resolutions were duly passed.  Following the meeting, Michael Gatenby, Chairman,
made the following statement:


'The first quarter has seen a continuation of the growth reported at the full
year.  Sales have continued to grow and were £2.814 million which includes
£0.119m from the brands acquired with the Dermapharm acquisition in February
2004.  This result compares to £10.412 million for the full year to February
2004.  At the final results we also highlighted our improving gross margin and
first quarter trading reflects this with a gross margin improvement to 52.3%,
compared to the 48.4% reported for the year ended February 2004.


On the product side there are early signs that the investment in the highly
targeted marketing of Symmetrel for use in the treatment of Parkinson's disease
is paying off and we will continue to promote this product through the current
financial year.  Ireland remains an excellent market for Nu-Seals, our heart
disease product, where we continue to build upon a high market share.  A newly
launched 28-day compliance pack has been well received.  In Dermatology we have
started to market the brands acquired from Dermapharm under the Alliance banner
and expect to see additional growth in these brands.



In the development pipeline, progress continues to be made on our two in-house
developments.  We are on track to commence in the second half of the calendar
year the Phase III clinical trials for our intra-vaginal misoprostol project for
labour induction.  Additionally, the management team continues to be very
excited by the opportunities in the area of sleep disorders and we will shortly
be seeking approval for the clinical trial protocols for our melatonin project
following the success of the formulation at Phase I.  We would expect to
undertake Phase III trials for the melatonin project towards the end of this
calendar year.



Overall, Alliance has had a positive start to the new financial year against its
clear growth strategy with some excellent progress made across the existing
products and development products in the pipeline.  We will continue to seek
cash generative acquisitions of established brands while exploiting the
potential of the existing business and bringing innovative new products into the
fold.'



Following completion of the formal business of the AGM, John Dawson, CEO, gave a
short presentation on the new product opportunities in obstetrics and sleep
disorders.  A copy of this presentation is available on Alliance's website at
www.alliancepharma.com.



                                    - ends -

For further information:



John Dawson, Managing Director
Alliance Pharma PLC
01249 466966



James Chandler/John Moriarty
Beattie Financial
020 7398 3300






                      This information is provided by RNS
            The company news service from the London Stock Exchange